Catalyst Wire Dossier Catalyst Wire Dossier

LX201

· Lux Biosciences, Inc.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for LX201, covering 2012-10-11 to 2012-10-11. Get the full timeline:

Most recent: Clinical Trial Update: Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk [Phase 3]

See pricing